With the now global outbreak of the novel SARS-like coronavirus, SARS-CoV-2 (2019-nCoV, COVID-19 virus), access to research tools has become critical to better understand the pathophysiology of the disease and develop specific and efficient novel therapeutics and prevention methods. Scientists identified the novel coronavirus as a group 2B CoV, distinct from the SARS-CoV. Genome sequencing indicated that SARS-CoV-2 (2019-nCoV) shares 79.5% sequence identity with SARS-CoV. It is therefore essential to assess SARS-CoV-2 specificity of research reagents. RayBiotech, distributed by tebu-bio in Europe, has made very special efforts to allow fast release of SARS-CoV-2 validated tools. This post introduces this new range of detection reagents, proteins and antibodies now available to boost COVID-19 research in Europe.